NCT06922253已完成1 期
An Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Four Period, Full-replicate, Oral Bioequivalence Study of Sacubitril and Valsartan 97 mg/103 mg Tablets of Ç.O.S.B., Karaağaç Mahallesi Fatih, Bulvarı No:32, Kapaklı/TEKİRDAĞ and Entresto® (Sacubitril and Valsartan) 97 mg/103 mg Tablets of Novartis Europharm Limited, Irija in Healthy, Adult, Human Subjects Under Fasting Condition.
Humanis Saglık Anonim Sirketi1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2024年12月28日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Peak Plasma Concentration (Cmax)
研究概览
简要总结
An open label, balanced, randomized, single dose, two treatment, two sequence, four period, full-replicate, oral bioequivalence Study of Sacubitril and Valsartan 97 mg/103 mg Tablets of HUMANİS SAĞLIK ANONİM ŞİRKETİ Ç.O.S.B., Karaağaç Mahallesi Fatih, Bulvarı No:32, Kapaklı/TEKİRDAĞ and Entresto® (Sacubitril and Valsartan) 97 mg/103 mg Tablets of Novartis Europharm Limited, Irija in healthy, adult, human subjects under fasting condition.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects aged between 18 and 45 years (both inclusive).
- •Subjects' weight within normal range according to normal values for Body Mass Index (between 18.50 and 30.00 kg/m2) (both inclusive) with minimum of 45 kg weight.
- •Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable range.
- •Subject with Creatinine Clearance ≥80 ml/min.
- •Subjects having clinically acceptable 12-lead electrocardiogram (ECG).
- •Subjects having clinically acceptable chest X-Ray (PA view), if taken.
- •Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
- •Subjects having negative urine alcohol test / breath alcohol test.
- •Non-smokers.
- •Subjects willing to adhere to the protocol requirements and to provide written informed consent.
- •For male Subjects:
- •Subjects willing to follow approved birth control methods (a double barrier method) for the duration of the study as judged by the investigator(s), such as (a double barrier method) condom with spermicide, Condom with diaphragm, or abstinence. Subjects willing to refrain from donating sperm during the study period
- •For Female Subjects: Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as intrauterine device (IUD), abstinence, bilateral tubal ligation or double barrier contraception, i.e., condom + diaphragm, condom + spermicidal or foam Postmenopausal for at least 1 year, or if less than 1 year, then following acceptable contraceptive measures as mentioned above
- •Subjects having negative urine pregnancy test at screening and negative serum β-hCG pregnancy test on admission day of period 01 (only for female subjects).
- •Female Subjects who are non-pregnant and non-lactating.
排除标准
- •Subjects having hypersensitivity to Sacubitril and Valsartan or related class of drugs or any of its excipients or heparin.
- •Subject with the serum potassium level >5.4 mmol/l during screening.
- •History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital or psychiatric disease or disorder.
- •Subjects who undergone any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 30 days prior to admission in period
- •History or presence of alcoholism or drug abuse.
- •History or presence of asthma, urticaria or other significant allergic reactions.
- •History or presence of significant gastric and/or duodenal ulceration.
- •History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
- •History or presence of cancer or basal or squamous cell carcinoma.
- •Subject having difficulty with donating blood.
- •Subjects having difficulty in swallowing solid dosage form like tablets or capsules.
- •Use of any prescribed medication or OTC medication including vaccines, vitamins and herbal remedies during last 30 days prior to admission in period
- •Subject having major illness within past 03 months.
- •Volunteer who have donated blood (1 unit) or participation in a drug research study within past 90 days prior to the first dose of the study drug.
- •Consumption of xanthine-containing products, tobacco containing products or alcohol or any alcohol containing products within 48.00 hours prior to admission in period
- •Consumption of grapefruit or grapefruit juice containing products within 72.00 hours prior to admission of period
- •Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
- •History or presence of significant easy bruising or bleeding.
- •History or presence of significant recent trauma.
- •Subjects who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.
- •Female subjects who are currently breast feeding.
研究组 & 干预措施
Sacubitril and Valsartan Tablets
Experimental
Sacubitril and Valsartan 97 mg / 103 mg Tablets
干预措施: Sacubitril and Valsartan-Test product (Drug)
Entresto® (Sacubitril and Valsartan) Tablets
Experimental
Entresto® (Sacubitril and Valsartan) 97 mg / 103 mg Tablets
干预措施: Sacubitril and Valsartan-Reference product (Drug)
结局指标
主要结局
Peak Plasma Concentration (Cmax)
时间窗: 48.00 hours
If the intra-subject CV of the reference formulation for Cmax is less than or equal to 30%, the conventional acceptance range of 80.00% - 125.00% for bioequivalence will be applied to Cmax.
Area Under the Curve from time zero to time of last measurable concentration (AUC0-t)
时间窗: 48.00 hours
For, AUC0-t, acceptance range for bioequivalence is 80.00 - 125.00% for 90% confidence intervals of the geometric least square means ratio (T/R).
次要结局
- Area Under the Curve from time zero to time infinite (AUC0-∞)(48.00 hours)
- Time to reach peak plasma concentration (Tmax)(48.00 hours)
- Plasma Elimination Half-Life (t1/2)(48.00 hours)
- The elimination rate constant (Kel)(48.00 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of Omeprazole Magnesium 20 mg DR Capsule Under Fed ConditionsHealthyNCT01045434Dr. Reddy's Laboratories Limited62
已完成
1 期
Comparative Bioavailability of XS004 (Dasatinib) Formulation G and SPRYCEL® (Dasatinib) in Healthy, Adult Subjects Under Fasting ConditionsBiological AvailabilityNCT05439408Xspray Pharma AB110
已完成
不适用
Bioequivalence Study of Nitrofurantoin 100 mg Capsules Under Fed ConditionsHealthyNCT00778583Ranbaxy Laboratories Limited40
Unknown
1 期
A Single Oral Dose, Crossover Comparative PK Study of WD-1603 in Healthy Subjects Under Fasting ConditionsParkinson DiseaseNCT04553978Hong Kong WD Pharmaceutical Co., Limited8
已完成
1 期
Bio-Equivalence Study of Budesonide Prolonged-release Tablets 9 Mg In Healthy Human Adult SubjectsHealthy SubjectsHuman VolunteersHealthy ParticipantsBioequivalenceNCT05519514Abbott56